Highlighting the immunohistochemical profile of melanocytomas: review.

The histological assessment of atypical melanocytic neoplasms is mandatory to ensure proper diagnosis and treatment. However, for some atypical lesions, expert pathologists report only moderate concordance in the diagnosis. In addition, certain atypical neoplasms have been coined differently in the literature. These designations include among others atypical and metastasizing Spitz tumor, malignant Spitz naevus, borderline and intermediate melanocytic tumor, and melanocytic tumor of uncertain malignant potential (MELTUMP) or Spitzoid melanocytic tumor of uncertain malignant potential (STUMP). These neoplasms are grouped here under the heading melanocytoma. Such melanocytic lesions have a benign outcome but exhibit an atypical and worrisome aspect. Rare individual cases of melanocytomas can progress to locoregional disease (agminate melanocytomas), and even beyond. At times, the distinction between melanocytoma and melanoma is difficult and may even be impossible. However, multipronged immunohistochemistry can help define malignancy risk stratification and therapeutic guidelines.

[1]  W. Mooi,et al.  Spitz Nevus Versus Spitzoid Melanoma: Diagnostic Difficulties, Conceptual Controversies , 2006, Advances in anatomic pathology.

[2]  Jason B Lee.  Spitz nevus versus melanoma: limitation of the diagnostic methodology exposed. , 2006, European journal of dermatology : EJD.

[3]  M. Mihm,et al.  Prognosticators of melanoma, the melanoma report, and the sentinel lymph node , 2006, Modern Pathology.

[4]  R. Barnhill.  The Spitzoid lesion: rethinking Spitz tumors, atypical variants, ‘Spitzoid melanoma’ and risk assessment , 2006, Modern Pathology.

[5]  Bruce R Smoller,et al.  Histologic criteria for diagnosing primary cutaneous malignant melanoma , 2006, Modern Pathology.

[6]  G. Piérard,et al.  Immunohistochemical investigation of &agr;1 (IV) and &agr;5 (IV) collagen chains in a broad spectrum of melanocytic tumours , 2005 .

[7]  J. Arrese,et al.  Immunohistochemical detection of incipient melanoma micrometastases. Relationship with sentinel lymph node involvement , 2005, Melanoma research.

[8]  M. Selim,et al.  Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis , 2005, Modern Pathology.

[9]  M. Cook.  Diagnostic pitfalls with melanocytic tumours , 2004 .

[10]  R. Vollmer.  Use of Bayes rule and MIB-1 proliferation index to discriminate Spitz nevus from malignant melanoma. , 2004, American journal of clinical pathology.

[11]  J. Mones,et al.  "Atypical" Spitz's nevus, "malignant" Spitz's nevus, and "metastasizing" Spitz's nevus: a critique in historical perspective of three concepts flawed fatally. , 2004, The American Journal of dermatopathology.

[12]  I. Fumal,et al.  Updating trends in cutaneous cancers in south-east Belgium. , 2004, Oncology reports.

[13]  P. Delvenne,et al.  Factor XIIIa-positive dendrocytes and proliferative activity of cutaneous cancers , 1996, Virchows Archiv.

[14]  J. Arrese,et al.  Immunohistochemical aid at risk stratification of melanocytic neoplasms. , 2004, International journal of oncology.

[15]  M. Piris,et al.  Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. , 2004, The American journal of pathology.

[16]  G. Wood,et al.  Apoptosis and melanoma: molecular mechanisms , 2003, The Journal of pathology.

[17]  K. Zainabadi,et al.  Minimal deviation melanoma. , 2002, Cancer treatment reviews.

[18]  Ning Li,et al.  Immunohistochemical Markers of Melanocytic Lesions: A Review of Their Diagnostic Usefulness , 2002, The American Journal of dermatopathology.

[19]  J. Naeyaert,et al.  Inter‐observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions , 2002, The Journal of pathology.

[20]  R. Bergman,et al.  MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the histopathologic differential diagnosis of Spitz nevi. , 2001, Journal of the American Academy of Dermatology.

[21]  J. Kril,et al.  A Zonal Comparison of MIB1-Ki67 Immunoreactivity in Benign and Malignant Melanocytic Lesions , 2000, The American Journal of dermatopathology.

[22]  W. Weyers,et al.  Angiomatoid Spitz nevus: a distinct variant of desmoplastic Spitz nevus with prominent vasculature. , 2000, The American Journal of dermatopathology.

[23]  G. Piérard,et al.  Vascular retardation in dormant growth-stunted malignant melanomas. , 1999, International journal of molecular medicine.

[24]  B. Smoller,et al.  Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[25]  R. Reed.  Dimensionalities: borderline and intermediate melanocytic neoplasia. , 1999, Human pathology.

[26]  C. Demirkesen,et al.  Eruptive widespread Spitz nevi: can pregnancy be a stimulating factor? , 1999, Journal of the American Academy of Dermatology.

[27]  M. Mihm,et al.  Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. , 1999, Human pathology.

[28]  S. Blacher,et al.  Fractal Quantification of the Microvasculature Heterogeneity in Cutaneous Melanoma , 1999, Dermatology.

[29]  C. Grin,et al.  The misdiagnosis of malignant melanoma. , 1999, Journal of the American Academy of Dermatology.

[30]  E. Calonje,et al.  Spitz tumors in children: a grading system for risk stratification. , 1999, Archives of dermatology.

[31]  R. Bergman,et al.  Apoptosis, Fas and Fas‐ligand expression in melanocytic tumors , 1999, Journal of cutaneous pathology.

[32]  S. McCarthy,et al.  Spitz nevus versus spitzoid malignant melanoma: an evaluation of the current distinguishing histopathologic criteria. , 1998, Human pathology.

[33]  G. Piérard,et al.  Stochastic relationship between the growth fraction and vascularity of thin malignant melanomas. , 1997, European journal of cancer.

[34]  O. Larsson,et al.  Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[35]  G. Collina,et al.  Atypical dermal nodules in benign melanocytic naevi , 1997, Histopathology.

[36]  J. Dowling,et al.  Spitz naevi misdiagnosed histologically as melanoma: prevalence and clinical profile. , 1997, The Australasian journal of dermatology.

[37]  N. Nikkels‐Tassoudji,et al.  NAEVOCYTE TRIGGERING BY RECOMBINANT HUMAN GROWTH HORMONE , 1996, The Journal of pathology.

[38]  E. Farmer,et al.  Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. , 1996, Human pathology.

[39]  R. Peachey,et al.  Agminate Spitz naevi occurring in an adult after the excision of a solitary Spitz naevus — report of a case and review of the literature , 1996, Clinical and experimental dermatology.

[40]  R. Bergman,et al.  The Pattern of HMB‐45 Antibody Staining in Compound Spitz Nevi , 1995, The American Journal of dermatopathology.

[41]  T. Flotte,et al.  Cutaneous melanoma and atypical spitz tumors in childhood , 1995, Cancer.

[42]  L. Golitz,et al.  Melanocytic nevi with focal atypical epithelioid cell components: a review of seventy-three cases. , 1994, Journal of the American Academy of Dermatology.

[43]  C. Cockerell,et al.  Comparative Analysis of Neovascularization in Primary Cutaneous Melanoma and Spitz Nevus , 1994, The American Journal of dermatopathology.

[44]  G. Piérard,et al.  The proliferative activity of cells of malignant melanomas. , 1984, The American Journal of dermatopathology.